Ibn Sina’s consolidated earnings per share (EPS) was Tk 21.46, compared to Tk 19.38 the previous year, according to a disclosure on the Dhaka Stock Exchange (DSE)

IBN Sina Pharmaceutical Industry secured a 44 percent year-on-year rise in profit in the January-March period of fiscal year 2023-24, which it attributed to an aggressive marketing strategy and proactive support from the management.

The Ibn Sina Pharmaceutical is going to invest Tk 10 crore in its subsidiary the Ibn Sina API Industry Ltd as part of its capital investment in order to purchase capital machineries, the company said today.